Journal: Bioactive Materials

Article Title: Countering postoperative immune suppression with a self-assembling dendritic cell nanovaccine

doi: 10.1016/j.bioactmat.2026.05.005

Figure Lengend Snippet: In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for Ki67 (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.

Article Snippet: Anti-Ki67 mouse mAb (Cat# GB121141-100), anti-CD3 mouse mAb (Cat# GB15014-100), FITC-conjugated goat anti-mouse IgG (H + L) (Cat# GB22301), and Cy5-conjugated goat anti-mouse IgG (H + L) (Cat# GB27301) for immunofluorescence assays, and DAB (SA-HRP) TUNEL apoptosis detection kit were supplied by Servicebio (Wuhan, China).

Techniques: In Vivo, Drug discovery, Staining, TUNEL Assay, Immunofluorescence

Journal: IBRO Neuroscience Reports

Article Title: TNKS1 mediates the PTEN-PI3K/AKT pathway to regulate glycolysis and proliferation in gliomas

doi: 10.1016/j.ibneur.2026.01.007

Figure Lengend Snippet: Inhibition of TNKS1 expression can suppress cell proliferation in glioma xenografts.HE staining to observe cell morphology in each group (A); immunohistochemistry to detect Ki-67 values in cells from each group (B), with an asterisk (*) indicating a significant difference compared to the TNKS1-siRNA NC group, P < 0.05. Scale bar = 50 μm.

Article Snippet: The primary antibody used was rabbit anti-Ki67 antibody (HA721115, 1:200, HUABIO, USA), which was incubated overnight at 4°C.

Techniques: Inhibition, Expressing, Staining, Immunohistochemistry

Journal: Bone & Joint Research

Article Title: Naringin targets TGF-β1-mediated angiogenesis to enhance the osteogenic effect of induced membrane

doi: 10.1302/2046-3758.155.BJR-2025-0412.R1

Figure Lengend Snippet: Vascular formation and cell proliferation results of the induced membrane in rats. a) First-stage surgery of induced membrane technique (IMT). The white arrow refers to the bone defect, and the green arrow indicates the polymethylmethacrylate (PMMA) spacer. b) Second-stage surgery of IMT. The yellow arrow refers to the bone grafting area. c) Gross view, haematoxylin and eosin (H&E) and Masson staining results of the induced membrane. The yellow arrows indicate blood vessels. d) Immunohistostaining of platelet endothelial cell adhesion molecule-1 (CD31) in the induced membrane. The yellow arrows indicate CD31-positive vessels. e) Immunohistostaining of von Willebrand factor (vWF) in the induced membrane. The yellow arrows indicate vWF-positive vessels. f) Immunohistostaining of antigen Kiel 67 (Ki67) in the induced membrane. N = 6/group. Each value is presented as the mean (SD). *p < 0.05, **p < 0.01, ***p < 0.001 versus the Control group; #p < 0.05, ##p < 0.01, ###p < 0.001 versus the L-Naringin group.

Article Snippet: The slices were incubated with anti-platelet endothelial cell adhesion molecule-1 (CD31) antibody (1:50, Abcam, UK, ab281583), anti-von Willebrand factor (vWF) antibody (1:1,000, Servicebio, China, GB11020), anti-antigen Kiel 67 (Ki67) antibody (1:500, Servicebio, GB121141 ), anti-TGF-β1 antibody (1:500, Abcam, ab215715), anti-Phospho-SMAD2 antibody (p-SMAD2, 1:100, Abcam, ab188334), and anti-Phospho-SMAD3 antibody (p-SMAD3, 1:100, Bioss, China, bs-5616R).

Techniques: Membrane, Staining, Control